To compare two different treatment modalities in the treatment of alopecia areata
Phase 3
- Conditions
- Health Condition 1: O- Medical and Surgical
- Registration Number
- CTRI/2023/01/048750
- Lead Sponsor
- DR BSA MEDICAL COLLEGE
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Clinically diagnosed cases of alopecia areata of scalp aged 18-60 years with
<25% scalp involvement.
• Patients with 1-5 patches of hair loss.
• Patient who gives consent for the study
Exclusion Criteria
Patients with alopecia totalis,alopecia universalis or Ophiasis.
1.Patient with history of diabetes,hypertension,thromboembolism,bleeding
disorders,abnormal coagulogram, patient already on steroid therapy,keloidal
tendencyetc.
2.Pregnant or lactating female.
3.Patient with any active skin infectionat the site of hair loss.
4.Patient who has taken topical or intralesional treatment within last 1 month
and oral treatment within last 3 months for alopecia areata.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the SALT Score to prove efficacy of platelet rich plasma vs.intralesional triamcinolone <br/ ><br>acetonide (10mg/ml) given 3weekly for 3 doses in the treatment of localized alopecia <br/ ><br>areata of the scalp (aged 18-60 years) as assessed by mean SALT scoring.Timepoint: 3,6 and 9 weeks follow up
- Secondary Outcome Measures
Name Time Method 1.To compare the efficacy as per Hair Regrowth Grade Scale (HRG) at 3, 6 & 9 <br/ ><br>weeks between two groups. <br/ ><br>2.To compare VAS for pain due to intralesional injection between the two groups. <br/ ><br>3.To compare the patient satisfaction score between two groups. <br/ ><br>4.To compare the relapse rates at 18 weeks in both groups. <br/ ><br>5.To compare the side effect profile between two groups.Timepoint: 0,3,6,9,18 WEEKS